NEW YORK (GenomeWeb) – OncoDNA announced today that it will help perform patient stratification in a Phase II precision medicine study in head and neck cancer being run by the European Organization for Research and Treatment of Cancer.
The trial is expected to enroll up to 257 patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing after first-line platinum-based chemotherapy. OncoDNA said that it will use next-generation sequencing and immunohistochemistry assays to analyze patient biopsies and identify potential biomarkers and molecular alterations that can be used to stratify trial participants into different treatment cohorts.
Additional terms of the arrangement were not disclosed.
Earlier this year, OncoDNA signed an agreement to investigate the use of its liquid biopsy technology in personalizing treatments for metastatic colon cancer. And in October, the firm said that it would supply tumor molecular profiling analysis for SOLTI's breast cancer screening program.